Zhejiang Puli Pharmaceuticals left oxyfluorosa tablets by the German Federal Drug and Medical Devices Authority (BfArM) market license.

Introduction: LVOFLOXacin (LVLX) is a fluoroquinoquinoxone antibacterial drug.
. Zhejiang Puli Pharmaceutical Co., Ltd., a wholly owned subsidiary of Hainan Puli Pharmaceutical Co., Ltd., recently received a 250 mg listing license from the German Federal Medicines and Medical Devices Administration ("BfArM").
LOX oral preparations can be used to treat the following mild, moderate, and severe infections caused by sensitive strains of the following bacteria in adults (18 years of age): hospital-obtained pneumonia; acute bacterial sinusitis; chronic bronchial Acute bacterial onset of inflammation; complex skin and skin structure infections; non-complex skin and skin soft tissue infections; chronic bacterial prostatitis; complex urinary tract infections; acute pyelonephritis; non-complex urinary tract infections; inhaled anthrax (after exposure).
1evofloxacin (LVLX) is a left-handed optical isomer of the fluoroquinoxone drug oxyfloxacin, with in-body antibacterial activity twice that of oxyfluorosa.
because of its strong antibacterial effect, broad antibacterial spectrum, with positive antibacterial after-effects, is currently a clinical anti-infection first-line drugs.
can be used to treat infections caused by designated susceptible bacteria in adults (up to 18 years of age).
is developed by First Pharmaceuticals (13th Co., Ltd.) and has been listed in more than 40 countries around the world.
.